Results 141 to 150 of about 5,304 (170)
Some of the next articles are maybe not open access.

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

open access: yesNew England Journal of Medicine
BACKGROUNDWhether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown.METHODSIn this ...
Daniel Lysak   +2 more
exaly   +4 more sources

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [PDF]

open access: yesNew England Journal of Medicine, 2016
Background Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).
Anna Schuh, Peter Hillmen, John M Pagel
exaly   +4 more sources

Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Patients With COVID-19 Requiring Hospitalization

open access: yesImmunoHorizons
The efficacy and safety of acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was evaluated in 2 phase 2 studies in hospitalized patients with coronavirus disease 2019 (COVID-19) who received acalabrutinib + best supportive care (BSC) versus BSC ...
Hans W. Prozesky   +2 more
exaly   +2 more sources

Analysis of Ventricular Arrhythmias and Sudden Death From Prospective, Randomized Clinical Trials of Acalabrutinib [PDF]

open access: yesBritish Journal of Haematology
This analysis investigated the incidence of sudden deaths (SDs) and non-fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient-years).
Jeff P Sharman   +2 more
exaly   +3 more sources

Acalabrutinib

Reactions Weekly, 2021
openaire   +2 more sources

EMA Review of Acalabrutinib for the Treatment of Adult Patients With Chronic Lymphocytic Leukemia

Oncologist, 2021
Christian Gisselbrecht   +2 more
exaly  

Home - About - Disclaimer - Privacy